Beijing Pharscin Innobio

Beijing Pharscin Innobio is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule drugs and protein degraders for oncology. As a subsidiary or strategic innovation arm associated with Chongqing Pharscin Pharmaceutical, the company leverages advanced platforms such as Proteolysis-targeting chimera (PROTAC) technology to address unmet medical needs in cancer treatment. Their pipeline includes several candidates targeting well-validated oncogenic drivers like BET proteins and CDK4/6, with a focus on overcoming resistance to existing therapies. The company operates research and development facilities in Beijing, aiming to bridge the gap between early-stage discovery and clinical proof-of-concept.